EP1872788A1 — External agent for treating wound
Assigned to Maruishi Pharmaceutical Co Ltd · Expires 2008-01-02 · 18y expired
What this patent protects
[Problems] The objective is to provide a new low-toxic drug for external use for intractable diseases, such as erosion, decubitus, and skin ulcer, that prevents cicatrization and reduces iodine accumulation on wound surfaces with sufficiently promoting healing. [Means for s…
USPTO Abstract
[Problems] The objective is to provide a new low-toxic drug for external use for intractable diseases, such as erosion, decubitus, and skin ulcer, that prevents cicatrization and reduces iodine accumulation on wound surfaces with sufficiently promoting healing. [Means for solving problem] Preparation of a wound treatment drug for external use containing oily bases and iodine but substantially no white soft sugar, which is a characteristic of the drug of this invention. The invented drug prevents infection through the wound surface due to a sufficient bactericidal effect of iodine, and promotes wound healing, prevents cicatrization and reduces iodine accumulation on the wound surface by maintenance of appropriate moisture in the wound surface due to a moisturizing effect of oily bases.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.